Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Keytruda Pembrolizumab Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Iclusig Ponatinib Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Complete
Zydelig Idelalisib Chronic lymphocytic leukemia Reimburse with clinical criteria and/or conditions Complete
Revlimid Lenalidomide Multiple Myeloma, newly diagnosed Reimburse with clinical criteria and/or conditions Complete
Brineura cerliponase alfa Neuronal Ceroid Lipofuscinosis Type 2 Reimburse with clinical criteria and/or conditions Complete
Aermony RespiClick fluticasone propionate Asthma Reimburse with clinical criteria and/or conditions Complete
Arbesda RespiClick fluticasone propionate / salmeterol xinafoate Asthma Reimburse with clinical criteria and/or conditions Complete
Mavenclad cladribine Multiple Sclerosis, relapsing-remitting Reimburse with clinical criteria and/or conditions Complete
Symtuza Darunavir/cobicistat/emtricitabine/tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Taltz ixekizumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete